International Society for Antiviral Research

Last updated
International Society for Antiviral Research (ICAR)
Formation1987;37 years ago (1987)
Type Scientific society
Headquarters Logan, Utah [1]
Location
  • United States
Membership
>400
President of the International Society for Antiviral Research
 Luis M Schang
Key people
President-elect David Durantel
Website www.isar-icar.com

The International Society for Antiviral Research (ISAR) is a scientific society that focuses on the discovery and clinical application of antiviral agents. It was founded in 1987 to encourage the exchange of information and collaborative research on the development of biological, and chemical antiviral agents.

Contents

ISAR sponsors the International Conference on Antiviral Research (ICAR), held yearly since 1988 when the second ICAR occurred in Williamsburg, Virginia. ISAR also provides scientific information through peer-reviewed scientific journals and administers several international awards. [2]

As of May 25,2024, the president of the society was Luis M Schang and the president-elect was David Durantel. [3] Previously, Johan Neyts was president from 2018-2020, succeeded as president by Kara Carter (2020-2022), and then Katherine Seley-Radtke (2022-2024). [4] [5]

Founding

The foundation for the International Society for Antiviral Research (ISAR) was laid at meetings held in Rotterdam, Netherlands (April 30 – May 3, 1985) [2] : 3, 23, 51  and in Il Ciocco, Italy (May 10-23, 1987) by NATO. [6] : 37  The society, in the persons of William M. Shannon, Earl R. Kern, and Richard J. Whitley registered articles of incorporation in the United States in the state of Alabama, on May 14, 1987. [7] : 6–7  The society's stated purpose was "the promotion and advancement of scientific knowledge in the area of antiviral scientific research for the benefit of all human beings". [7]

The original Board of Directors of ISAR included Alfons Billiau (KU Leuven, Leuven, Belgium), Erik De Clercq (Rega Institute, KU Leuven), A. Kirk Field (Squibb Institute for Medical Research, Princeton, New Jersey), George J. Galasso (National Institutes of Health (U.S.)), Earl R. Kern (University of Utah, Salt Lake City, Utah), William M. Shannon (Southern Research Institute, Birmingham, Alabama), and Richard J. Whitley (University of Alabama at Birmingham). [7] [8] Richard Whitley became the first president of ISAR, serving from 1988-1990, with De Clercq as president elect. [8]

Conferences

The International Conference on Antiviral Research (ICAR) has been held every year since 1988. Its location circulates between the United States, Europe, and the rest of the world, reflecting the distribution of its members. [9] The last annual meeting, 37th ICAR was held in Gold Coast, Australia, May 20-24, 22024. The next annual meeting, 38th ICAR, will be held in March 13-17, 2025 in Las Vegas, NV, USA.

It is generally agreed that the second ICAR was a meeting held in Williamsburg, Virginia in 1988, which was advertised as such. [2] : 3, 23 

Neither the Rotterdam meeting (1985) nor the Italy meeting (1987) was identified at the time as "the first" International Conference for Antiviral Research (ICAR). Since then, each meeting has been described as the first ICAR meeting by different proponents. [2] : 3, 23  George Galasso and others consider Rotterdam the first meeting because at that meeting Galasso, Erik De Clercq and Alfons Billiau discussed formation of a Society and decided to approach Earl Kern and Richard Whitley. Erik De Clercq has emphasized the 1987 NATO meeting at Il Ciocco because ideas for both ISAR and ICAR were developed there. [2] : 3, 23 

Publications

Awards given

Presidents

Related Research Articles

<span class="mw-page-title-main">Gertrude B. Elion</span> American biochemist and pharmacologist (1918–1999)

Gertrude "Trudy"Belle Elion was an American biochemist and pharmacologist, who shared the 1988 Nobel Prize in Physiology or Medicine with George H. Hitchings and Sir James Black for their use of innovative methods of rational drug design for the development of new drugs. This new method focused on understanding the target of the drug rather than simply using trial-and-error. Her work led to the creation of the anti-retroviral drug AZT, which was the first drug widely used against AIDS. Her well known works also include the development of the first immunosuppressive drug, azathioprine, used to fight rejection in organ transplants, and the first successful antiviral drug, acyclovir (ACV), used in the treatment of herpes infection.

<span class="mw-page-title-main">Aciclovir</span> Antiviral medication used against herpes, chickenpox, and shingles

Aciclovir, also known as acyclovir, is an antiviral medication. It is primarily used for the treatment of herpes simplex virus infections, chickenpox, and shingles. Other uses include prevention of cytomegalovirus infections following transplant and severe complications of Epstein–Barr virus infection. It can be taken by mouth, applied as a cream, or injected.

<span class="mw-page-title-main">George H. Hitchings</span> Nobel Prize-winning American doctor (1905–1998)

George Herbert Hitchings was an American medical doctor who shared the 1988 Nobel Prize in Physiology or Medicine with Sir James Black and Gertrude Elion "for their discoveries of important principles for drug treatment", Hitchings specifically for his work on chemotherapy.

<span class="mw-page-title-main">Vidarabine</span> Chemical compound

Vidarabine or 9-β-D-arabinofuranosyladenine (ara-A) is an antiviral drug which is active against herpes simplex and varicella zoster viruses.

<span class="mw-page-title-main">Rega Institute for Medical Research</span> Belgian biomedical research institute

The Rega Institute for Medical Research is a Belgian scientific establishment that is part of the Catholic University of Leuven (Leuven) in central Belgium. The Rega Institute is an interfacultary biomedical research institute of the Catholic University of Leuven and consists of departments of medicine and pharmacology.

Douglas D. Richman is an American infectious diseases physician and medical virologist. Richman's work has focused on the HIV/AIDS pandemic, since its appearance in the early 1980s. His major contributions have been in the areas of treatment, drug resistance, and pathogenicity.

<span class="mw-page-title-main">Rudi Pauwels</span> Belgian pharmacologist and entrepreneur

Rudi Pauwels is a Belgian pharmacologist and biotech entrepreneur.

<span class="mw-page-title-main">Antonín Holý</span>

Antonín Holý was a pioneering Czech scientist. He specialised in the field of chemistry and cooperated on the development of important antiretroviral drugs used in the treatment of HIV and hepatitis B. He was involved in the creation of the most effective drug in the treatment of AIDS. Antonín Holý is the author of more than 450 papers, 400 scientific discoveries and holds 60 patents. With more than 400 discoveries to his credit, his work has affected millions of people with viral diseases such as HIV/AIDS and hepatitis B and many other viral diseases. In 2008 he received an Honorary Professorship at the University of Manchester's School of Chemistry.

FV-100, also known as Cf1743, is an orally available nucleoside analogue drug with antiviral activity. It may be effective against shingles.

<span class="mw-page-title-main">William Prusoff</span>

William Herman Prusoff was a pharmacologist who was an early innovator in antiviral drugs, developing idoxuridine, the first antiviral agent approved by the FDA, in the 1950s, and co-developing stavudine, one of the earliest AIDS drugs, in the mid-1980s.

<span class="mw-page-title-main">John C. Martin (businessman)</span> American billionaire businessman

John Charles Martin was an American billionaire businessman, and the former executive chairman (2016–2018) and CEO (1996–2016) of the American biotechnology company Gilead Sciences. He joined Gilead Sciences in 1990 as vice president for research and development. Gilead is known for developing drugs such as Atripla and commercializing Sovaldi (sofosbuvir) for the treatment of the liver virus hepatitis C. Martin is the recipient of a number of awards, including the Biotechnology Heritage Award (2017).

Erik De Clercq M.D. Ph.D., (1941) is a Belgian physician and biologist. He studied medicine at the Catholic University of Leuven. He did research and later became a professor at the Department of Medicine, where he specialised in microbiology and immunology. He worked at the Rega Institute for Medical Research. He is one of the founders and the second president of the International Society for Antiviral Research.

Masanori Baba is a Japanese professor of microbiology who works at the Kagoshima University in Kagoshima, Japan. On May 20, 2013, he was awarded the Gertrude B. Elion Memorial Award by the International Society for Antiviral Research for his research into anti-AIDS drugs.

<span class="mw-page-title-main">MK-608</span> Chemical compound

MK-608 is an antiviral drug, an adenosine analog. It was originally developed by Merck & Co. as a treatment for hepatitis C, but despite promising results in animal studies, it was ultimately unsuccessful in clinical trials. Subsequently it has been widely used in antiviral research and has shown activity against a range of viruses, including Dengue fever, tick-borne encephalitis virus, poliovirus, and most recently Zika virus, in both in vitro and animal models. Since it has already failed in human clinical trials previously, it is unlikely MK-608 itself will be developed as an antiviral medication, but the continuing lack of treatment options for these emerging viral diseases means that much research continues using MK-608 and related antiviral drugs.

Michael J. Sofia is a chemist whose main research focus is hepatitis C virus and hepatitis B virus drug discovery. He was a co-recipient of the Lasker-DeBakey Clinical Medical Research Award for his work on hepatitis C in 2016 and of the Gertrude B. Elion Memorial Award from the International Society for Antiviral Research in 2017.

Raymond F. Schinazi is an Egyptian organic medicinal chemist at Emory University with expertise in antiviral agents, pharmacology, and biotechnology. His research focuses on developing treatments for infections caused by human immunodeficiency virus (HIV), hepatitis B (HBV), hepatitis C (HCV), herpes, dengue fever, zika, chikungunya, and other emerging viruses. These treatment options include antiviral agents as well as synthetic, biochemical, pharmacological and molecular genetic approaches, including molecular modeling and gene therapy.

<span class="mw-page-title-main">North-methanocarbathymidine</span> Chemical compound

North-Methanocarbathymidine (N-MCT) is an antiviral drug which is an analogue of thymidine, and shows activity against herpesviruses, orthopoxviruses and HIV, though it has not been introduced into clinical use.

Tomáš Cihlář is a Czech biochemist known for his role in the development of remdesivir. A specialist in virology, Cihlář holds the positions of Senior Director, Biology, and Vice-President at American pharmaceutical company Gilead Sciences. As a student, Cihlář assisted fellow biochemist Antonín Holý in developing Viread, the primary drug used to fight HIV infection.

Johan Hendrik Neyts is a Belgian virologist. He is head of The Neyts-lab of Virology, Antiviral Drug and Vaccine Research, which is part of the Laboratory of Virology and Chemotherapy at the Rega Institute for Medical Research, and full professor of virology at the Faculty of Medicine of KU Leuven. During the 2019-2020 coronavirus pandemic, Neyts came to national prominence as an expert on the (re)search for antiviral drugs and vaccines against SARS-CoV-2.

Katherine Seley-Radtke is an American medicinal chemist who specializes in the discovery and design of novel nucleoside or nucleotide based enzyme inhibitors that may be used to treat infections or cancer. She has authored over 90 peer-reviewed publications, is an inventor of five issued US patents, and is a professor in the department of chemistry and biochemistry at the University of Maryland, Baltimore County. Her international impact includes scientific collaborations, policy advising and diplomatic appointments in biosecurity efforts.

References

  1. ↑ Cumulative List of Organizations Described in Section 170 (c) of the Internal Revenue Code of 1986. Vol. 2. Department of the Treasury, Internal Revenue Service. 1997. p. 268.
  2. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Vere Hodge, R. Anthony, ed. (2019). The International Society for Antiviral Research: The Third Decade 2008-2017 (PDF). International Society for Antiviral Research.
  3. ↑ "NOTICE FROM ISAR: ICAR2024". International Society for antiviral research. 2024. Retrieved 26 May 2024.
  4. 1 2 3 4 "ISAR Officers". International Society for antiviral research. Retrieved 12 May 2020.
  5. 1 2 Seley-Radtke, Katherine (May 10, 2020). "Remdesivir explained – what makes this drug work against viruses?". The Street. Retrieved 12 May 2020.
  6. ↑ "Report on the 25th ICAR, 16–19 April 2012, Sapporo, Japan". Antiviral Chemistry and Chemotherapy. 23 (1): 35–43. August 2012. doi:10.3851/IMP2385. S2CID   207964758.
  7. 1 2 3 4 5 The International Society for Antiviral Research: The First Decade 1987-1997 (PDF). International Society for Antiviral Research. 1998.
  8. 1 2 Colacino, Joseph M. (April 2013). "Professor De Clercq and 25 Years of International Collaboration on Antiviral Research". Antiviral Chemistry and Chemotherapy. 23 (2): 57–58. doi:10.3851/IMP2395. PMID   22992324. S2CID   207735250.
  9. 1 2 De Clercq, Erik (2016). "ICAR THROUGH THE YEARS" (PDF). ISAR NEWS (Newsletter of the International Society for Antiviral Research). 25 (3): 16–18. Retrieved 26 May 2024.
  10. ↑ "Antiviral Research". Microsoft Academic. Retrieved 12 May 2020.[ dead link ]
  11. ↑ Field, Hugh J. (February 2015). "AVCC 1990–2015 – A journal to combine antiviral biology and antiviral chemistry enters the third era". Antiviral Chemistry and Chemotherapy. 24 (1): 1–2. doi:10.1177/2040206615574801. PMC   5890501 . PMID   26149261.
  12. 1 2 3 4 5 Shannon, William M., ed. (2008). The International Society for Antiviral Research: The Second Decade 1998-2007 (PDF). International Society for Antiviral Research.[ permanent dead link ]
  13. ↑ "Professor Griffiths receives Gertrude Elion Memorial Award". University College London. 23 March 2018. Retrieved 12 May 2020.
  14. 1 2 3 4 5 "ISAR presents the following awards and opportunities as listed below". International Society for Antiviral Research. Retrieved 12 May 2020.
  15. ↑ "Gertrude Elion Memorial Award". isar-icar.com. Retrieved 2024-03-21.
  16. ↑ "William H. Prusoff, Ph.D". Yale Medicine Magazine. Yale University. 2001. Retrieved 12 May 2020.
  17. ↑ "Piet Herdewijn receives Antonin Holý Memorial Lecture award May 2014". Rega Institute KU Leuven. 2014. Retrieved 12 May 2020.
  18. 1 2 Vere Hodge, R. Anthony (28 June 2018). "Meeting report: 30th International Conference on Antiviral Research, in Atlanta, GA, USA". Antiviral Chemistry and Chemotherapy. 26: 204020661878392. doi: 10.1177/2040206618783924 . PMC   6043914 . PMID   29954186.
  19. ↑ "Richard J. Whitley". University of Alabama at Birmingham School of Medicine. Retrieved 12 May 2020.
  20. ↑ "John C. Martin. Ph.D., MBA". The University of Alabama at Birmingham. Retrieved 12 May 2020.[ permanent dead link ]
  21. ↑ Jung, Rhonda (November 13, 2006). "Southern Research Institute CEO Jack Secrist Recognized For Contributions In Cancer Drug Research". BioSpace. Retrieved 12 May 2020.
  22. ↑ "Genelabs Appoints Amy K. Patick, Ph.D. Vice President, Biological Sciences". BusinessWire. April 14, 2008. Retrieved 12 May 2020.
  23. ↑ "PTC Therapeutics expands management team". PTC Therapeutics. Jan 24, 2014. Retrieved 12 May 2020.
  24. ↑ "Phillip A. Furman". Florida Inventors Hall of Fame. 10 April 2018. Retrieved 12 May 2020.
  25. ↑ "Immune Therapeutics, Inc. Announces Advisory Board Appointments". GlobeNewsWire (Press release). October 22, 2019. Retrieved 12 May 2020.
  26. ↑ "5th IAAASS 2020 CONFIRMED SPEAKERS". 5th IAAASS 2020. Retrieved 12 May 2020.
  27. ↑ "Interview: Belgian virologist calls for global efforts against new viruses". Xinhua. 2020-02-07. Retrieved 12 May 2020.[ dead link ]
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.